Johnson & Johnson sees device slowdown in third quarter
This article was originally published in Clinica
Competition from Boston Scientific in the drug-eluting stent market took its toll on Johnson & Johnson's medical device and diagnostic sales growth in the third quarter. Revenues rose by just 3.6% operationally, to $4bn - although positive currency effects helped boost reported growth to 7%. A year earlier, third-quarter growth was 16.3% operationally and 20.3% on a reported basis.